Teleflex Receives FDA Clearance for ARROW-ClarkTM VectorFlow™ Chronic Hemodialysis Catheter
July 22 2014 - 7:00AM
Business Wire
Teleflex Incorporated (NYSE:TFX), a leading global provider of
medical devices for critical care and surgery, has announced it has
received FDA 510(k) clearance to market its ARROW-Clark™
VectorFlow™ Chronic Hemodialysis Catheter. Designed by Dr. Timothy
Clark, M.D., the VectorFlowTM Catheter features a symmetrical tip
design that allows ease of placement and sustained high flows with
minimal recirculation.
“Providing clinicians with the ARROW-Clark™ VectorFlow™ Catheter
continues a series of new product introductions that demonstrates
our commitment to enhance patient outcomes and improve ease of use
for clinicians,” said Linda Beneze, President and General Manager,
Specialty Division. “We are proud to add the VectorFlow™ Catheter
to our portfolio.”
The ARROW-Clark™ VectorFlow™ Catheter is the only catheter with
an innovative tip designed to produce a helical, three-dimensional
transition of blood entering and leaving the catheter.1
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical
devices for a range of procedures in critical care and surgery. Our
mission is to provide solutions that enable healthcare providers to
improve outcomes and enhance patient and provider safety.
Headquartered in Wayne, PA, Teleflex employs approximately 11,400
people worldwide and serves healthcare providers in more than 150
countries. Additional information about Teleflex can be obtained
from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, Arrow, ARROW-Clark and VectorFlow are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates.©
2014 Teleflex Incorporated. All rights reserved. MC-000213
References:
1. Clark T, et al. Computational Flow Dynamics and Preclinical
Assessment of a Novel Hemodialysis Catheter.Seminars in Dialysis.
2012.
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor
Relations610-948-2836jake.elguicze@teleflex.comwww.teleflex.com
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024